Enhanced SPARC expression in the tumor-associated stroma correlates with a poor prognosis for patients with non-small cell lung cancers (NSCLC) [19] and pancreatic adenocarcinomas [20], but not for those with bladder cancers [21]. This evidence concerns the gene SPARC and non-small cell lung carcinoma.